Which Chinese New Drugs Are Poised to Take ASCO by Storm?
Time：
2026-05-28 20:39
Author：
xieyijun
CPIC 2026 | Vaccine Innovation & Global Expansion Session – Agenda Debut
Explore the next step of innovation and going global with pioneers in the vaccine industry.
Time：
2026-05-28 15:04
Author：
xieyijun
U.S. "cutting off" Chinese biotechnology: anxiety and backlash
The game behind the expansion of the COINS Act
Time：
2026-05-28 08:16
Author：
xieyijun
Acknowledging progress is as important as recognizing gaps.
Time：
2026-05-27 08:11
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务